Topotecan for ovarian cancer.

The Cochrane Database of Systematic Reviews
L H PengT X Wu

Abstract

Chemotherapeutic agents such as topotecan can be used to treat ovarian cancer. The effects of using topotecan as a therapeutic agent have not been previously been systematically reviewed. To systematically evaluate the effectiveness and safety of topotecan for the treatment of ovarian cancer. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), (Issue 4, 2006); Cochrane Gynaecological Cancer Review Group (CGCRG) Specialised Register (Cochrane Library Issue 4, 2006); MEDLINE (January 1990 to 27 July 2006); EMBASE (January 1990 to 27 July 2006); The European Organization for the Research and Treatment of Cancer (EORTC) database (to 1 August 2006); CBM (Chinese Biomedical Database) (January 1990 to 27 July 2006). Randomised controlled trials (RCTs) which randomized patients with ovarian cancer to single or combined use of topotecan versus interventions without topotecan, or different remedies of topotecan. Two review authors independently extracted and analysed data. Six studies including 1323 participants were eligible for this review (Gordon 2004a; Gore 2001a; Gore 2002; Hoskins 1998; Huinink 2004; Placido 2004) All studies, as reported, were identified as being of poor methodological quality. Topotecan had ...Continue Reading

References

May 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A P KudelkaJ J Kavanagh
Feb 1, 1996·Controlled Clinical Trials·A R JadadH J McQuay
Dec 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J CreemersW W Ten Bokkel Huinink
Mar 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A PawinskiP H de Mulder
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W ten Bokkel HuininkJ F Heron
May 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S GwytherA Jiménez-Lacave
Sep 23, 1997·Gynecologic Oncology·E M SwisherT J Herzog
Jun 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P HoskinsB Zee
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H HochsterJ Speyer
Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P McGuireC J Dunton
Jun 1, 2000·Gynecologic Oncology·H A NielsenS A Engelholm
Apr 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M GoreS Z Fields
Jul 7, 2001·BMJ : British Medical Journal·P JüniM Egger
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonA J Lacave
Oct 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L Clarke-PearsonS Z Fields
Dec 26, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M GoreS Z Fields
Jun 12, 2002·Current Treatment Options in Oncology·Martee L Hensley
Sep 27, 2002·The Oncologist·Robert Morris, Adnan Munkarah
Nov 7, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J SehouliUNKNOWN NOGGO study group
Oct 22, 2003·Anti-cancer Drugs·Al BensonIgnace Vergote
Nov 6, 2003·Gynecologic Oncology·U MatulonisUNKNOWN Dana Farber-Harvard Cancer Care
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W ten Bokkel HuininkUNKNOWN International Topotecan Study Group
Apr 22, 2004·Gynecologic Oncology·Silvana ChiaraUNKNOWN GONO (Italian Gruppo Oncologico del Nord-Ovest)
May 6, 2004·Cancer Chemotherapy and Pharmacology·George P StathopoulosDimosthenis V Skarlos
Jul 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sabino De PlacidoSandro Pignata
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anil K SoodJoel I Sorosky

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.